Co-occurring KEAP1, CDKN2A, and SMARCA4 loss-of-function alterations have recently emerged as poor prognostic biomarkers in KRAS G12C-mutant non-Sq NSCLC treated with the KRAS G12C inhibitors, sotorasib and adagrasib60. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.